Veradermics, Incorporated
MANE
$103.83
+5.40%
Veradermics, Incorporated is a clinical-stage biopharmaceutical company focused on developing therapeutics for prevalent aesthetic and dermatological conditions, operating in a single segment of allocating resources and assessing performance. As a niche player in the dermatology space, it distinguishes itself by targeting pervasive treatment challenges with a specialized pipeline. The current investor narrative centers on the company's recent IPO in February 2026, its rapid share price appreciation since listing, and the market's anticipation of clinical milestones and potential commercialization, despite the absence of revenue and ongoing R&D investments.…
MANE
Veradermics, Incorporated
$103.83
Investment Opinion: Should I buy MANE Today?
Rating: Buy. The consensus is Strong Buy with an average target of $163.50, implying 67% upside. The thesis is that MANE's specialized pipeline in dermatology addresses large unmet needs, and with ample cash to fund development, the risk-reward is favorable for investors with high risk tolerance. Key supports: 6 analysts all rate it Strong Buy, the low target of $135 still offers 38% upside, the stock has gained 113.6% in 6 months, and the market cap of $1.32B suggests significant growth potential. Risks: clinical trial failures, regulatory delays, and dilution. This Buy would be downgraded to Hold if the stock falls below $90 or if clinical data disappoints. The stock is overvalued on traditional metrics but fairly valued on future potential.
Sign up to view all
MANE 12-Month Price Forecast
The AI model leans bullish due to strong analyst support and a solid cash position, but confidence is medium given the lack of revenue and clinical-stage risks. The stock's future depends on successful pipeline execution. Upgrades would occur if positive trial data emerges, while downgrades would follow any clinical failure or significant cash burn.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Veradermics, Incorporated's 12-month outlook, with a consensus price target around $163.50 and implied upside of +57.5% versus the current price.
Average Target
$163.50
0 analysts
Implied Upside
+57.5%
vs. current price
Analyst Count
—
covering this stock
Price Range
$135 - $182
Analyst target range
The target price range spans from a low of $135.00 to a high of $182.00, indicating a 35% spread between the low and high estimates. The high target of $182.00 assumes successful clinical development and potential blockbuster sales, while the low target of $135.00 still implies a 38% upside, suggesting even the most conservative analyst sees significant value. Recent ratings from Jefferies, Citigroup, and Leerink Partners have all been positive, with no downgrades, reinforcing the bullish sentiment.
Bulls vs Bears: MANE Investment Factors
The bull case is currently stronger, driven by unanimous analyst bullishness, a robust cash position, and a compelling market opportunity. However, the bear case highlights the lack of revenue, negative book value, and extreme volatility. The central tension is whether MANE's pipeline will successfully commercialize, justifying its premium valuation, or whether clinical setbacks will erode investor confidence. The stock's future hinges on upcoming clinical data and regulatory milestones.
Bullish
- Strong Buy consensus with 67% upside: All 6 analysts rate MANE a Strong Buy, with an average target of $163.50, implying 67% upside from the current $97.93. The low target of $135 still offers 38% upside, indicating even the most bearish analyst sees significant value.
- Rapid share appreciation since IPO: MANE has surged 113.6% over the past 6 months, from $46.62 at IPO to $97.93, and reached a high of $131.24. This momentum reflects strong market confidence in its pipeline and commercial potential.
- High liquidity with current ratio of 16.7: The company holds ample cash to fund operations, with a current ratio of 16.66, indicating it can sustain R&D spending for several years without immediate financing pressure. This reduces near-term dilution risk.
- Focused pipeline in large dermatology market: MANE targets prevalent aesthetic and dermatological conditions, a market with high demand and significant unmet need. Successful development could lead to blockbuster sales, as reflected in analyst revenue estimates up to $1.75B.
Bearish
- Pre-revenue with widening losses: MANE has zero revenue and net losses widened to -$27.2M in Q1 2026 from -$21.8M in Q4 2025, driven by R&D spending of $20.9M. Without commercialization, losses will continue to escalate.
- Negative book value and undefined valuation: The price-to-book ratio is -10.94, indicating negative shareholder equity due to accumulated losses. Traditional valuation metrics like PE and PS are meaningless, making the stock difficult to justify on fundamentals.
- Extreme volatility and drawdown risk: The stock has a max drawdown of -24.5% and a short ratio of 4.76, indicating high volatility and potential for sharp declines. Recent 1-month performance is -9.1%, underperforming the S&P 500 by 14.6%.
- Clinical-stage execution risk: As a clinical-stage biotech, MANE faces significant risk of trial failures or regulatory setbacks. Any negative data could trigger a sharp sell-off, as seen in similar companies.
MANE Technical Analysis
Veradermics has exhibited a powerful uptrend since its IPO in February 2026, with the stock surging from a 52-week low of $32.00 to a high of $131.24, representing a 310% gain from the low. The current price of $97.93 sits at 74.6% of the 52-week range, indicating the stock is still in the upper portion of its trading band but has pulled back from the highs. This positioning suggests strong momentum but also potential overextension, as the stock has more than doubled from its IPO price of $46.62 in just six months.
Beta
—
—
Max Drawdown
-24.8%
Largest decline past year
52-Week Range
$32-$131
Price range past year
Annual Return
—
Cumulative gain past year
| Period | MANE Return | S&P 500 |
|---|---|---|
| 1m | -9.2% | -0.9% |
| 3m | +11.7% | +5.6% |
| 6m | +101.3% | +15.0% |
| 1y | — | +18.1% |
| ytd | — | +12.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MANE Fundamental Analysis
Veradermics is a pre-revenue clinical-stage biotech, with zero revenue reported for Q1 2026 and all prior quarters, reflecting its early development stage. The company's net loss widened to -$27.2 million in Q1 2026 from -$21.8 million in Q4 2025, driven by increased R&D spending of $20.9 million, up from $18.2 million. The trajectory shows escalating losses as clinical programs advance, which is typical for biotechs but underscores the need for successful pipeline execution.
Quarterly Revenue
$0.0B
2026-03
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
N/A
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MANE Overvalued?
Given that Veradermics has negative net income and EBITDA, the most appropriate valuation metric is the price-to-sales ratio, but since revenue is zero, the PS ratio is undefined. Instead, we rely on the price-to-book ratio, which is -10.94, indicating negative book value due to accumulated losses. The trailing PE is -15.86 and forward PE is -36.44, both negative and not meaningful for comparison. The negative PEG ratio of -0.0099 further confirms the lack of earnings-based valuation.
PE
-15.9x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-18.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks are substantial: MANE has no revenue, and its net loss widened to -$27.2M in Q1 2026, with R&D expenses of $20.9M. The company's negative book value (-$10.94 PB) and negative cash flow from operations indicate heavy reliance on external funding. While the current ratio of 16.66 provides a cushion, continued losses will deplete cash, potentially forcing dilutive equity raises. The negative PCF ratio of -18.49 underscores the lack of cash generation, and the company's ability to reach profitability is uncertain.
FAQ
The key risks are: 1) Clinical failure - any trial setback could cause a sharp sell-off, as seen in similar biotechs. 2) Financial risk - the company has no revenue and is burning cash, with a net loss of $27.2M in Q1 2026, potentially leading to dilution. 3) Market risk - the stock is highly volatile, with a max drawdown of -24.5% and a short ratio of 4.76, indicating potential for sharp declines. 4) Regulatory risk - delays or rejections from the FDA could derail the pipeline.
Analysts are bullish, with a Strong Buy consensus and an average target of $163.50, implying 67% upside. The bull case targets $182, the base case $163.50, and the bear case $70-100. The most likely scenario is the base case, assuming clinical progress continues. However, the stock's future hinges on trial results and regulatory milestones, making the forecast highly uncertain.
On traditional metrics, MANE is overvalued: it has negative earnings, negative book value, and no revenue, making PE and PS ratios meaningless. However, the market is pricing in future potential, as evidenced by analyst revenue estimates up to $1.75B. Compared to peers, the valuation is speculative, but the strong buy ratings suggest analysts believe the upside justifies the risk. The stock is likely fairly valued if its pipeline succeeds, but overvalued if it fails.
MANE is a high-risk, high-reward opportunity. With a Strong Buy consensus and 67% upside to the average target, it offers significant potential, but the lack of revenue and clinical-stage risks make it unsuitable for conservative investors. For those with a high risk tolerance and a long-term horizon, it could be a good buy, but only as a small position. The biggest downside risk is a clinical trial failure, which could lead to a 30-40% decline.
MANE is more suitable for long-term investment, given its clinical-stage nature and potential for multi-year development. Short-term trading is risky due to extreme volatility and the lack of fundamental support. Investors should be prepared to hold for at least 3-5 years to allow pipeline milestones to materialize. The stock's beta is not provided, but its 1-month relative strength of -14.6% indicates high sensitivity to market sentiment, making it unsuitable for short-term traders.